
Please try another search
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Robert Charles Bishop | - | 2013 | Executive Director |
Thomas Duthy | - | 2024 | Non-Executive Director |
Christian Schirvel | - | 2017 | Veterinary Clinical Advisory Board Member |
Michael Thurn | - | 2024 | MD, CEO & Director |
Kathryn MacFarlane | 59 | 2024 | Director |
Barbara Kitchell | - | 2017 | Veterinary Advisory Board Member |
Angela Frimberger | - | 2017 | Veterinary Clinical Advisory Board Chair |
Marcus Paul Hughes | - | 2024 | Director |
Sergio Duchini | - | 2024 | Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review